Details for New Drug Application (NDA): 218021
✉ Email this page to a colleague
NDA 218021 describes HYDROXYUREA, which is a drug marketed by Barr, Barr Labs Inc, Endo Operations, Leading, Qilu, and Roxane, and is included in seven NDAs. It is available from twelve suppliers. Additional details are available on the HYDROXYUREA profile page.
The generic ingredient in HYDROXYUREA is hydroxyurea. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the hydroxyurea profile page.
The generic ingredient in HYDROXYUREA is hydroxyurea. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the hydroxyurea profile page.
Summary for 218021
| Tradename: | HYDROXYUREA |
| Applicant: | Qilu |
| Ingredient: | hydroxyurea |
| Patents: | 0 |
Suppliers and Packaging for NDA: 218021
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| HYDROXYUREA | hydroxyurea | CAPSULE;ORAL | 218021 | ANDA | Qilu Pharmaceutical Co., Ltd. | 67184-0607 | 67184-0607-1 | 100 CAPSULE in 1 BOTTLE (67184-0607-1) |
| HYDROXYUREA | hydroxyurea | CAPSULE;ORAL | 218021 | ANDA | Somerset Therapeutics, LLC | 70069-820 | 70069-820-01 | 100 CAPSULE in 1 BOTTLE (70069-820-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 500MG | ||||
| Approval Date: | Mar 6, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
